20784-50-3
20784-50-3 结构式
基本信息
异补骨脂乙素
异补骨脂查耳酮
异补骨脂查尔酮
补骨脂乙素标准品
补骨脂乙素对照品
补骨脂乙素(异补骨脂酮
异补骨脂查尔酮(标准品)
异补骨脂查尔酮/补骨脂乙素
补骨脂乙素(异补骨脂查尔酮)
ISOBAVACHALCONE
Isobacachalcone
Isobavachalcone/Corylifolinin
Corylifolinin(Isobavachalcone)
(E)-4,2',4'-Trihydroxy-3'-prenylchalcone
2',4,4'-Trihydroxy-3'-prenyl-trans-chalcone
(E)-1-[2,4-Dihydroxy-3-(3-methyl-2-butenyl)phenyl]-3-(4-hydroxyphenyl)-2-propen-1-one
(E)-1-(2,4-Dihydroxy-3-(3-methylbut-2-en-1-yl)phenyl)-3-(4-hydroxyphenyl)prop-2-en-1-one
(2E)-1-[2,4-Dihydroxy-3-(3-methylbut-2-en-1-yl)phenyl]-3-(4-hydroxyphenyl)prop-2-en-1-one
物理化学性质
制备方法
![2-Propen-1-one, 1-[2,4-bis(methoxymethoxy)-3-(3-methyl-2-buten-1-yl)phenyl]-3-[4-(methoxymethoxy)phenyl]-, (2E)-](/CAS/20210305/GIF/1449202-18-9.gif)
1449202-18-9
![2-Propen-1-one, 1-[2,4-dihydroxy-3-(3-methyl-2-buten-1-yl)phenyl]-3-(4-hydroxyphenyl)-](/CAS/20210305/GIF/54676-49-2.gif)
54676-49-2
以化合物（CAS: 1449202-18-9）为原料合成1-(2,4-二羟基-3-(3-甲基-2-丁烯-1-基)苯基)-3-(4-羟基苯基)丙-2-烯-1-酮的一般步骤如下： 通用方法： 1. 在0℃下，将化合物13（100 mg，0.22 mmol）溶于甲醇（2 mL）中，缓慢加入1N盐酸水溶液（1 mL）。 2. 将反应混合物加热至50℃，维持该温度反应6小时。 3. 反应完成后，将混合物冷却至室温，随后在真空条件下除去甲醇。 4. 加入乙酸乙酯（10 mL）进行萃取，分离有机层和水层。 5. 水层用乙酸乙酯（2×10 mL）进一步萃取，合并所有有机层。 6. 有机层用无水硫酸镁干燥，过滤后真空浓缩，得到粗产物。 7. 粗产物通过硅胶快速色谱法纯化，洗脱剂为正己烷/乙酸乙酯（15:1），得到目标产物巴伐利亚酮（53 mg，收率75%），为黄色固体。 注：该方法同样适用于以化合物22（100 mg，0.22 mmol）为底物制备化合物1，反应条件与上述相同，最终得到化合物1（53 mg，收率75%），为黄色固体。
参考文献：
[1] Tetrahedron Letters, 2014, vol. 55, # 4, p. 897 - 899
[2] Tetrahedron Letters, 2014, vol. 55, # 4, p. 897 - 899
[3] European Journal of Medicinal Chemistry, 2015, vol. 92, p. 439 - 448
| 报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
| 2025/05/22 | HY-13065 | 补骨脂乙素 Isobavachalcone | 20784-50-3 | 1 mg | 320元 |
| 2025/05/22 | HY-13065 | 补骨脂乙素 Isobavachalcone | 20784-50-3 | 5 mg | 804元 |
| 2025/05/22 | HY-13065 | 补骨脂乙素 Isobavachalcone | 20784-50-3 | 10mM * 1mLin DMSO | 924元 |
常见问题列表
IC50: 7.92 μM (OVCAR-8 cell)
Isobavachalcone (6.0-48.0 μM; 72 hours; OVCAR-8, PC3, A549, MCF-7, L-02 and HUVEC cells) treatment inhibits the proliferation of human cancer cells. Isobavachalcone inhibits PC3, A549, MCF-7, L-02 and HUVEC cells growth with IC50 values of 15.06 μM, 32.2 μM, 28.29 μM, 31.61 μM and 31.3 μM, respectively.
Isobavachalcone (0-18 μM; 6 hours; OVCAR-8 and PC3 cells) treatment results in a concentration-and time-dependent down-regulation of the Ser-473 phosphorylation of Akt and GSK3b phosphorylation.
Isobavachalcone (0-18 μM; 72 hours; OVCAR-8 and PC3 cells) treatment causes apoptosis via caspase- and ROS-involved mitochondrial pathway.
Cell Proliferation Assay
| Cell Line: | OVCAR-8, PC3, A549, MCF-7, L-02 and HUVEC cells |
| Concentration: | 6.0-48.0 μM |
| Incubation Time: | 72 hours |
| Result: | Inhibited the proliferation of human cancer cells. |
Western Blot Analysis
| Cell Line: | OVCAR-8 or PC3 cells |
| Concentration: | 0 μM, 6 μM, 12 μM, and 18 μM |
| Incubation Time: | 6 hours |
| Result: | A concentration-and time-dependent down-regulation of the Ser-473 phosphorylation of Akt. GSK3b phosphorylation was also inhibited in a concentration- and time-dependent manner. |
Apoptosis Analysis
| Cell Line: | OVCAR-8 cells and PC3 cells |
| Concentration: | 0 μM, 6 μM, 12 μM, and 18 μM |
| Incubation Time: | 72 hours |
| Result: | Led to dose dependent increase of apoptosis. |
Isobavachalcone (20 mg/kg; intraperitoneal injection; for 0.5-24 hours; female Kunming mice) treatment results in an increase in blood glucose levels, reaching a maximum within 1 hour and maintaining until 4 hours post-dosing.
| Animal Model: | Seven-week-old specific pathogen-free female Kunming mice (18-22 g) |
| Dosage: | 20 mg/kg |
| Administration: | Intraperitoneal injection; for 0.5, 1, 2, 4, 6, 8, 12, 24 hours |
| Result: | Increased in blood glucose levels. |